Overview

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborators:
Rongchang Biopharmaceutical
Zhengda Tianqing Pharmaceutical Group Co., Ltd.
Treatments:
Cisplatin